eGFP expression constructs using lipofectamine 2000 (Invitrogen) according to the manufacturer’s recommendations. The next day, cells were stimulated with TNF muteins, as indicated, and fixed with PBS/4% PFA for 30 minutes on ice at point in time zero. Then cells were permeabilized with PBS/0.1% Triton-X100 for 10 minutes at room temperature. Unspecific binding sites were blocked with PBS/4% BSA for 30 min and cells were subse- quently incubated with primary antibodies for 60 min followed by the incubation with appropriate fluorescence-labeled secondary antibodies for 45 min in PBS/2% BSA. After staining the nuclei with DAPI the cells were mounted with Fluoromount G (Southern Biotech). The labeled cells were analyzed by wide-field fluores- cence microscopy (CellObserver with Colibri LED modules, Carl Zeiss, Jena, Germany) or by confocal laser scanning microscopy (LSM710, Carl Zeiss). The analysis of the obtained data and imaging was performed with the AxioVision Rel 4.7 (Carl Zeiss; CellObserver) or ZenLightEdition (Carl Zeiss; LSM710) software. Isotype or secondary antibodies control stainings were used to determine background fluorescence and to adjust the intensity of specific stainings. References 1. Wajant H, Pfizenmaier K, Scheurich P (2003) Tumor necrosis factor signaling. Cell Death Differ 10: 45–65. 2. McCoy MK, Tansey MG (2008) TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 5: 45. 3. Pfizenmaier K, Szymkowski DE (2011) Workshop Summary: Introduction to Rational Design of New Means for Therapeutic Modulation of Function of the TNF Family. Adv Exp Med Biol 691: 487–491. 4. Amor S, Puentes F, Baker D, van der Valk P (2010) Inflammation in neurodegenerative diseases. Immunology 129: 154–169. 5. Anonymous (1999) TNF neutralization in MS: results of a randomized, placebo- controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 53: 457–465. 6. Faustman D, Davis M (2010) TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov 9: 482–493. 7. Marchetti L, Klein M, Schlett K, Pfizenmaier K, Eisel UL (2004) Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase- dependent NF-kappa B pathway. J Biol Chem 279: 32869–32881. 8. Dolga AM, Granic I, Blank T, Knaus HG, Spiess J, et al. (2008) TNF-alpha- mediates neuroprotection against glutamate-induced excitotoxicity via NF- kappaB-dependent up-regulation of K2.2 channels. J Neurochem 107: 1158–1167. 9. Fontaine V, Mohand-Said S, Hanoteau N, Fuchs C, Pfizenmaier K, et al. (2002) Neurodegenerative and neuroprotective effects of tumor Necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci 22: RC216. 10. Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, et al. (2001) TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 4: 1116–1122. 11. Akassoglou K, Bauer J, Kassiotis G, Pasparakis M, Lassmann H, et al. (1998) Oligodendrocyte apoptosis and primary demyelination induced by local TNF/ p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy. Am J Pathol 153: 801–813. 12. Loetscher H, Stueber D, Banner D, Mackay F, Lesslauer W (1993) Human tumor necrosis factor alpha (TNF alpha) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors. J Biol Chem 268: 26350–26357. 13. Krippner-Heidenreich A, Grunwald I, Zimmermann G, Kuhnle M, Gerspach J, et al. (2008) Single-chain TNF, a TNF derivative with enhanced stability and antitumoral activity. J Immunol 180: 8176–8183. 14. Boschert V, Krippner-Heidenreich A, Branschadel M, Tepperink J, Aird A, et al. (2010) Single chain TNF derivatives with individually mutated receptor binding sites reveal differential stoichiometry of ligand receptor complex formation for TNFR1 and TNFR2. Cell Signal 22: 1088–1096. 15. Grell M, Douni E, Wajant H, Lohden M, Clauss M, et al. (1995) The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83: 793–802. 16. Rauert H, Wicovsky A, Muller N, Siegmund D, Spindler V, et al. (2010) Membrane tumor necrosis factor (TNF) induces p100 processing via TNF receptor-2 (TNFR2). J Biol Chem 285: 7394–7404. Neuroregeneration by a TNFR2 Agonist Quantification and statistical analysis To quantify protein amounts, detected by immunoblot blot analysis, films were scanned and integrated optical densities were calculated using ImageJ. Integrated optical densities were corrected for background intensities. For quantification of nuclear translocation of NFkB in immunofluorescence experiments, the number of cells with NFkB positive nuclei of at least 200 cells per experiment and condition was determined. Normal distribution was analyzed by Shapiro-Wilk normally test. Statistical analysis was performed by the Tukey range test. P,0.05 was considered significant. Acknowledgments LUHMES cells were a kind gift of Marcel Leist (University of Konstanz, Germany). Author Contributions Conceived and designed the experiments: RF OM KP. Performed the experiments: RF OM MS. Analyzed the data: RF OM MS HW PS KP. Wrote the paper: RF OM MS HW PS KP. 17. Lotharius J, Barg S, Wiekop P, Lundberg C, Raymon HK, et al. (2002) Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesence- phalic cell line. J Biol Chem 277: 38884–38894. 18. Lotharius J, Falsig J, van Beek J, Payne S, Dringen R, et al. (2005) Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway. J Neurosci 25: 6329–6342. 19. Schildknecht S, Poltl D, Nagel DM, Matt F, Scholz D, et al. (2009) Requirement of a dopaminergic neuronal phenotype for toxicity of low concentrations of 1- methyl-4-phenylpyridinium to human cells. Toxicol Appl Pharmacol 241: 23–35. 20. Scholz D, Poltl D, Genewsky A, Weng M, Waldmann T, et al. (2011) Rapid, complete and large-scale generation of post-mitotic neurons from the human LUHMES cell line. J Neurochem. 21. Krippner-Heidenreich A, Tubing F, Bryde S, Willi S, Zimmermann G, et al. (2002) Control of receptor-induced signaling complex formation by the kinetics of ligand/receptor interaction. J Biol Chem 277: 44155–44163. 22. Grell M, Scheurich P, Meager A, Pfizenmaier K (1993) TR60 and TR80 tumor necrosis factor (TNF)-receptors can independently mediate cytolysis. Lympho- kine Cytokine Res 12: 143–148. 23. Fischer R, Maier O, Naumer M, Krippner-Heidenreich A, Scheurich P, et al. (2011) Ligand-induced internalization of TNF receptor 2 mediated by a di- leucin motif is dispensable for activation of the NFkappaB pathway. Cell Signal 23: 161–170. 24. Nicholson KM, Anderson NG (2002) The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14: 381–395. 25. Noshita N, Lewen A, Sugawara T, Chan PH (2002) Akt phosphorylation and neuronal survival after traumatic brain injury in mice. Neurobiol Dis 9: 294–304. 26. Gary DS, Mattson MP (2001) Integrin signaling via the PI3-kinase-Akt pathway increases neuronal resistance to glutamate-induced apoptosis. J Neurochem 76: 1485–1496. 27. Yano S, Morioka M, Fukunaga K, Kawano T, Hara T, et al. (2001) Activation of Akt/protein kinase B contributes to induction of ischemic tolerance in the CA1 subfield of gerbil hippocampus. J Cereb Blood Flow Metab 21: 351–360. 28. Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, et al. (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson’s disease. Prog Neurobiol 65: 135–172. 29. Grell M, Zimmermann G, Gottfried E, Chen CM, Grunwald U, et al. (1999) Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J 18: 3034–3043. 30. Wallach D, Engelmann H, Nophar Y, Aderka D, Kemper O, et al. (1991) Soluble and cell surface receptors for tumor necrosis factor. Agents Actions Suppl 35: 51–57. 31. Holler N, Tardivel A, Kovacsovics-Bankowski M, Hertig S, Gaide O, et al. (2003) Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol 23: 1428–1440. 32. Bergman H, Deuschl G (2002) Pathophysiology of Parkinson’s disease: from clinical neurology to basic neuroscience and back. Mov Disord 17 Suppl 3: S28–40. PLoS ONE | www.plosone.org 10 November 2011 | Volume 6 | Issue 11 | e27621